Mesentech has developed a tissue-selective drug delivery system that utilizes novel chemistry to target pharmaceuticals specifically to musculoskeletal tissue, minimizing exposure to non-target organs. Their first clinical program focuses on delivering prostaglandin to enhance the body's regenerative processes for muscle and bone repair.
Funding
$27.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic drug administration often results in off-target effects, leading to toxicity and reduced efficacy, particularly when treating musculoskeletal conditions. High systemic doses are frequently required to achieve therapeutic concentrations in the target tissue, increasing the risk of adverse events.
Solution
Mesentech has developed a tissue-selective drug delivery platform that utilizes novel chemical conjugates to target pharmaceuticals specifically to musculoskeletal tissue. This targeted approach minimizes drug exposure to non-target organs, reducing systemic toxicity and improving the therapeutic index. Their lead clinical program, MES1022, leverages this technology to deliver prostaglandin E2 (PGE2) directly to muscle and bone, enhancing the body's natural regenerative processes for tissue repair. By concentrating the drug at the site of injury or degeneration, Mesentech aims to accelerate healing and improve patient outcomes.
Target Audience
The primary target audience includes patients with musculoskeletal injuries or degenerative conditions, as well as clinicians seeking more effective and targeted therapies for tissue repair and regeneration.
Features
- Proprietary chemical conjugation technology for tissue-specific drug delivery
- Selective targeting of musculoskeletal tissue, including muscle and bone
- Reduced systemic exposure and toxicity compared to traditional drug administration
- Enhanced therapeutic efficacy through localized drug concentration
- Lead candidate, MES1022, delivering prostaglandin E2 (PGE2) for regenerative medicine applications
- Potential applications in a range of musculoskeletal conditions, including muscle injuries and bone fractures